The Atypical Teratoid Rhabdoid Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Atypical Teratoid Rhabdoid Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Atypical Teratoid Rhabdoid Tumor. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Atypical Teratoid Rhabdoid Tumor and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Atypical Teratoid Rhabdoid Tumor by 16 companies/universities/institutes. The top development phase for Atypical Teratoid Rhabdoid Tumor is preclinical with six drugs in that stage. The Atypical Teratoid Rhabdoid Tumor pipeline has 17 drugs in development by companies and one by universities/ institutes. Some of the companies in the Atypical Teratoid Rhabdoid Tumor pipeline products market are: F. Hoffmann-La Roche, Scorpius and Novartis.
The key targets in the Atypical Teratoid Rhabdoid Tumor pipeline products market include Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1), DNA, and D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2).
The key mechanisms of action in the Atypical Teratoid Rhabdoid Tumor pipeline product include Phosphatidylinositol 3 Kinase (PI3K or EC 2.7.1.137) Inhibitor with one drug in Preclinical. The Atypical Teratoid Rhabdoid Tumor pipeline products include 11 routes of administration with the top ROA being Oral and five key molecule types in the Atypical Teratoid Rhabdoid Tumor pipeline products market including Small Molecule, and Oncolytic Virus.
Atypical Teratoid Rhabdoid Tumor overview
Atypical teratoid rhabdoid tumor (ATRT) is a rare and fast-growing cancerous tumor of the brain and spinal cord. About half of these tumors begin in the cerebellum or brain stem. ATRT often appears to result from changes in a gene that normally makes proteins to stop tumor growth. In ATRT, this gene does not function properly, the protein is not made and tumor growth is uncontrolled. More than 90% of cases of ATRT are related to this gene defect. While this defect commonly occurs only within the cancer, this gene defect may be inherited.
For a complete picture of Atypical Teratoid Rhabdoid Tumor’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
